nomic; children Granulocyte colony-stimulating factor (G-CSF) has been used to reduce the morbidity of autologous peripheral blood progenitor cell (PBPC) transplantation. Previous studies have demonstrated faster granulocyte recovery, shorter hospitalization and duration of fever and antibiotic administration with the use of G-CSF after transplant. [1] [2] There are different strategies in the utilized dose 3 and in the timing of the initiation of G-CSF after autologous PBPC transplantation (early vs delayed use). 4, 5 However, a controversial issue is the economic advantage of using G-CSF following PBPC transplantation. Some reports have established economic benefits of the administration of G-CSF after infusion, 3, [6] [7] but there has been no prospective trial addressing the economic consequences of the use of G-CSF following PBPC transplantation in children. There is a prospective randomized trial of G-CSF after autologous blood stem cell transplantation in children, which only analyzes clinical benefits. 8 We report here the first prospective study in children to evaluate the clinical and economic consequences of using G-CSF following autologous PBPC transplantation.
Patients and methods

Patient characteristics
Between January 1999 and December 2003, 117 pediatric patients underwent autologous PBPC transplantations for hematological malignancies and solid tumors in our institution. All patients were randomly assigned into one of two groups: the treatment group that received G-CSF (Filgrastim; Amgen, Thousand Oaks, CA, USA) at a dose of 10 mg/kg/day starting on day þ 5 until the absolute neutrophil count (ANC) was 40.5 Â 10 9 /l (n ¼ 51) or the control group that did not receive G-CSF postinfusion (n ¼ 66). Table 1 summarizes patient characteristics. There were no statistically significant differences in the demographic characteristics between the two groups. Informed consent was obtained in all cases using the protocols and forms approved by our institution's Ethical Committee.
Mobilization and collection
PBPC were mobilized with G-CSF subcutaneously, twice a day, at a total dose of 24 mg/kg/day, for 4 consecutive days before starting apheresis in all cases. Collections were carried out on day þ 5 using a Cobe Spectra cell separator (Cobe, Lakewood, CO, USA) through a central venous catheter by large-volume leukapheresis. Details of apheresis procedures have been reported previously.
9,10
Conditioning regimen
In general, the preparatory regimen for patients with solid tumors consisted of oral busulfan (4 mg/kg/day Â 4 days) and intravenous (i.v.) melphalan (140 mg/m 2 /day Â 1 day). ALL patients were conditioned with TBI (4 Gy/day Â 3 days) and i.v. cyclophosphamide (60 mg/kg/day Â 2 days) and AML patients with oral busulfan (4 mg/kg/day Â 4 days) and i.v. cyclophosphamide (60 mg/kg/day Â 2 days). Other myeloablative regimens were used for the remaining patients according to institutional protocols or cooperative trials (Table 1) .
Supportive care
Patients were nursed in single rooms with reverse-barrier isolation and HEPA-filtered air. Cotrimoxazole was given at a dose of 8 mg/kg/day for Pneumocystis carinii prophylaxis. When the regimen included busulfan, clonazepam and heparin were added for prophylaxis of seizures and veno-occlusive disease, respectively. On day 0, collected cells were infused after thawing. All patients were grafted with a minimum of 2.0 Â 10 6 /kg CD34 þ cells. Platelets were transfused if the platelet counts decreased below 10-15 Â 10 9 /l or in case of bleeding, and red blood cells were given to maintain a hemoglobin (Hb) level 48 g/dl. All transfusion products were irradiated before use. Febrile neutropenia was treated with broad-spectrum empiric antibiotic therapy. Amphotericin B was used for persistent fever after 3-5 days. Patients unable to maintain an adequate oral caloric intake were fed with parenteral nutrition. Discharge criteria included neutrophil engraftment and control of medical problems.
Study end points, definitions, clinical variables analyzed and cost analysis
Study end points were engraftment kinetics, supportive care and treatment costs. The study was approved by the ethical committee.
Neutrophil engraftment was defined as the first of 3 consecutive days with an ANC 40.5 Â 10 9 /l. Early platelet engraftment was defined as the time to achieve a platelet count 420 Â 10 9 /l for 3 consecutive days without transfusion support. Long-term platelet engraftment was defined as the time to achieve a platelet count 450 Â 10 9 /l for 3 consecutive days.
The duration of hospitalization was defined as the number of days from infusion to discharge from hospital.
Pretransplantation variables included age, gender, diagnosis, disease status at transplantation, conditioning regimen used and the number of CD34 þ cells infused. The postinfusion variables analyzed for the clinical outcome and cost analysis were as follows: day to neutrophil and platelet engraftment, platelet and red blood cells transfused, antibiotics required, days of morphine and inotropics, parenteral nutrition days and the duration of hospital stay.
Cost analysis was performed according to a previously reported model 11 obtained by a multiple linear regression. The main determinants of total costs of autologous PBPC transplantation were as follows: TBI-based conditioning, platelet units transfused, days of hospital and intensive care unit (ICU) stay and number of CD34 þ cells infused. The model obtained was:
Randomization and statistical analysis
Randomization was carried out centrally and stratified according to patients and transplantation variables. Data are expressed as the median and range. Kaplan-Meier estimates were calculated for engraftment kinetics. Student's test with two-sided P-values, nonparametric MannWhitney U-test and w 2 with continuity correction were used when indicated. Results were considered significant if the P-value was o0.05.
Results
Hematopoietic recovery
All patients engrafted, with a median time to ANC 40.5 Â 10 9 /l of 10 days and platelets 450 Â 10 9 /l of 14 days. Administration of G-CSF significantly accelerated neutrophil recovery. The median time to achieve ANC 40.5 Â 10 9 /l was 10 days (range: 7-14) in the G-CSF group and 11 days (range: 8-21) in the control group (Po0.009). Table 1 Patients and transplant characteristics Early platelet engraftment was similar in both groups, with a median of 12 days (P ¼ NS). However, long-term platelet engraftment was faster in the control group; the median time to achieve 450 Â 10 9 /L platelets was 14 days (range: 11-71) in the control group and 15 days (range: 9-100) in the G-CSF group (Po0.005). As the number of CD34 þ cells infused is the most important factor for hematopoietic recovery after autologous PBPC transplantation, we analyzed separately the patients who received more or less than 5 Â 10 6 /kg CD34 þ cells. The time to ANC 40.5 Â 10 9 /l was faster with G-CSF in both groups (10 vs 11 days). In the patients who received more than 5 Â 10 6 /kg CD34 þ cells, the use of G-CSF was associated with a delayed early and long-term platelet recovery. However, early and long-term platelet engraftment in patients who received less than 5 Â 10 6 /kg CD34 þ cells were similar with or without G-CSF (see Table 2 ).
Supportive care
The patients who did not receive G-CSF had less platelet transfusions than the patients in the G-CSF group (Table 3) 
Cost analysis
The costs were similar in both groups calculated according to the model previously reported, 11 although there was a trend toward higher total costs in the group with G-CSF following transplantation. Thus, the median cost was 8146.82 euros (range: 2595.21-52089.67) and 7873.34 euros (range: 2877.53-17893.43) with or without G-CSF, respectively (P ¼ 0.1). These differences were lower in the group of patients who received less than 5 Â 10 6 /kg CD34 þ cells (8441.93 with G-CSF and 8277.62 without G-CSF, P ¼ 0.7).
Discussion
Hematopoietic growth factors such as G-CSF have been used after autologous bone marrow transplant to enhance the engraftment and shorten the duration of neutropenia. 12, 13 Since both early and committed hematopoietic progenitors are more frequent in the mobilized PBPC population compared to unmanipulated bone marrow, 14 the role of cytokines after PBPC transplantation is controversial with respect to indications, efficacy and cost. The American Society of Clinical Oncology recommended the administration of colony-stimulating factors after PBPC infusion in adult patients. 15 Several previous studies in adults have demonstrated a faster myeloid engraftment and clinical benefits with the administration of G-CSF following PBPC transplantation. McQuaker et al 3 assessed the clinical benefit of filgrastim after PBPC transplantation in patients with lymphoproliferative disorders. They found more rapid neutrophil engraftment (10 vs 14 days, Po0.0001) and shortened antibiotic duration and inpatient stay (13 vs 16 days, P ¼ 0.0003) with the use of G-CSF after infusion. Tarella et al 7 analyzed two groups of 20 Table 2 Kinetics engraftment according to the number of CD34+ cells infused were also reduced with G-CSF administration. Later, Demirer et al 2 evaluated the effect of G-CSF administration on peritransplant morbidity in patients with hematologic malignancies and solid tumors. The administration of G-CSF was associated with a faster granulocyte recovery, shorter hospitalization and shorter period of fever and nonprophylactic antibiotic administration.
However, all these studies were performed in adult patients, while few trials have been carried out with pediatric patients. In 1998, a European panel 16 recommendation on the use of colony-stimulating factors in children stated that G-CSF should be used routinely as an adjuvant in autologous, but not allogeneic bone marrow transplant or autologous PBPC transplants, and suggested that prospective studies are required to draw evidence-based guidelines. In 1998, Kawano et al 8 evaluated the effectiveness of exogenous G-CSF in accelerating hematopoietic recovery after PBPC transplantation in 74 children diagnosed with hematologic malignancies and solid tumors. The neutrophil engraftment was faster in the treatment group than in the control group (11 vs 12 days, P ¼ 0.046). However, platelet recovery to 420 Â 10 9 /l was significantly longer in the treatment group (26 vs 16 days, P ¼ 0.009) and 450 Â 10 In a previous retrospective study, we analyzed the clinical consequences of using G-CSF after PBPC transplantation in children, and the administration of G-CSF did not demonstrate clinical benefit. 18 We designed a prospective, randomized study to analyze the clinical and economic repercussions of the administration of G-CSF, at the same dose that we used in the retrospective study, after PBPC transplantation in pediatric patients. We found accelerated neutrophil recovery with G-CSF and similar early platelet engraftment. However, long-term platelet engraftment was faster in the control group. This delayed recovery of platelets is in accord with the Kawano results. 8 The use of G-CSF resulted in slower platelet recovery. The main differences with the studies performed in adults are the lesser difference in neutrophil engraftment in children using G-CSF (only 1 day vs 4 days in adults) and the delayed recovery of platelets in pediatric patients with G-CSF. The reasons may be the differences not only in the quantity of PBPC in the grafts in children and adults but also the quality of autografted CD34 þ cells influencing postgraft hematopoietic recovery. CD34 þ cells in children may have a higher BM repopulating activity than in adults and both the reconstituting potential and quantity of stem cells are superior in children 19 and this might reduce the potential benefit of G-CSF in accelerating postgraft hematopoietic recovery. As the most critical factor in the time to neutrophil engraftment after autologous PBPC transplantation is the number of CD34 þ cells infused, the potentially higher cell dose infused in children reduces the benefit of the use of G-CSF after infusion in a pediatric population. Thus, we analyzed separately the patients who received more or less than 5 Â 10 6 /kg CD34 þ cells. In the patients who received more than 5 Â 10 6 /kg CD34 þ cells, the use of G-CSF was associated with a delayed early and long-term platelet recovery. However, early and long-term platelet engraftment and platelet requirements in patients who received less than 5 Â 10 6 /kg CD34 þ cells was similar with or without G-CSF (4 vs 3 U, P ¼ NS). These data support the possible indication of using G-CSF after PBPC transplantation in children for the group of patients with a lower collected number of CD34 þ cells (o5 Â 10 6 / kg). We did not find significant differences between using G-CSF and not for antibiotic days and hospitalization days, as opposed to the studies in adults. 2, 3, 7 This may be due to a rapid recovery of neutrophils after PBPC transplantation in children; hence, any further acceleration from growth factor administration may be difficult to assess. The early engraftment translated into a lesser use of antibiotics.
There are few studies in adults that analyze the repercussion on the costs of using G-CSF after PBPC transplantation. McQuaker et al 3 found a potential saving of over 1000 pounds per procedure for patients who received G-CSF and Tarella 7 et al showed a cost reduction of approximately 16% in the G-CSF group. The study by Colby et al 4 included children and found that despite the additional cost of G-CSF, the reduction in the hospitalization and antibiotic therapy with early (day þ 1) G-CSF administration, resulted in 11% cost savings overall per transplant.
To the best of our knowledge, ours is the first prospective randomized study that analyzes the economic consequences of the administration of G-CSF after infusion of PBPC in a pediatric population. The total costs of the procedure were similar in both groups, calculated according to the model previously reported, although there was a trend toward higher total costs in the group with G-CSF following transplantation. Platelet engraftment was delayed and transfusion requirements were greater in the group of patients who used G-CSF, influencing the duration of hospitalization and the costs. These differences were lower in the group of patients who received less than 5 Â 10 6 /kg CD34 þ cells.
In conclusion, the clinical benefit of faster neutrophil engraftment with G-CSF after transplant could be offset by the delayed recovery of platelets and a trend toward higher costs. Therefore, the standard application of G-CSF in children following PBPC transplantation should be reviewed. A possible indication is the group of patients with a lower yield of CD34 þ cells.
